Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002319 · ClinicalTrials.gov registry record · Phase 3
A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma
A Phase 3 study, sponsored by Sequus Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00002319: Completed Phase 3 study, sponsored by Sequus Pharmaceuticals.
NCT00002319 is a Phase 3 study that has completed, run by Sequus Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002319, a Phase 3 study, has completed, sponsored by Sequus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
To evaluate the safety and effectiveness of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the long-term treatment of AIDS-related Kaposi's sarcoma (KS) in patients who previously had good responses to DOX-SL in controlled studies of limited duration, or those with KS who discontinued treatment with another Kaposi's sarcoma therapy because of inadequate efficacy or unacceptable toxicity. To provide a defined protocol for Kaposi's sarcoma patients for whom DOX-SL therapy is indicated.
Interventions
- DRUG Doxorubicin hydrochloride (liposomal)
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002319
The ClinicalTrials.gov registry entry for NCT00002319 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Sequus Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Doxorubicin hydrochloride (liposomal) is the first listed.
NCT00002319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002319 about?
NCT00002319 is a clinical study titled "A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma". To evaluate the safety and effectiveness of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the long-term treatment of AIDS-related Kaposi's sarcoma (KS) in patients who previously had good responses to DOX-SL in controlled studies of limited duration, or those with KS who discontinued treat...
What is the current status of trial NCT00002319?
This trial is currently completed. It is a Phase 3 study.
What interventions are being tested in trial NCT00002319?
The interventions under investigation include: Doxorubicin hydrochloride (liposomal) (DRUG).
Who is sponsoring clinical trial NCT00002319?
This trial is sponsored by Sequus Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.